C alcineurin is the only Ca
2+ /calmodulin-dependent serine/ threonine protein phosphatase; it is a heterodimer composed of a 61-kDa catalytic subunit (calcineurin A subunit [CnA] ) and a 19-kDa regulatory subunit (calcineurin B subunit [CnB] ) (1, 2) . The enzyme is expressed in many different tissues and cells and is recognized as a modulator of T cell activation (3, 4) , neuronal excitability (5), apoptosis (6, 7) , and cardiac hypertrophy (8, 9) . Calcineurin is one of the most important functional proteins in immune system, which activates NFATc by dephosphorylating it. Activated NFATc is translocated into nucleus and then upregulates the expression of IL-2, which, in turn, stimulates the growth and differentiation of T cell and B cells (10, 11) . The CnB 2/2 thymocytes lose all calcineurin activity and are defective in positive but not negative selection (12) . The role of CnB was traditionally thought to be to regulate the phosphatase activity of CnA. However, in recent years, it has been shown that the CnB is not just a simple protein as the regulatory subunit of CnA. Cytosolic CnB can interact with tubulin, heat shock protein 60 (13) , procaspase-3 (14) , and PSMA7 (15) and therefore plays very important role in apoptosis and the proteasome pathway, which are not dependent on the phosphatase activity of CnA. In previous work, we found that i.p. injection of CnB promoted peritoneal macrophage proliferation (data not shown), enhanced phagocytic activity (16) , increased the secretion of cytokines, and prolonged the survival of mice bearing H22 ascites tumors (17) . We therefore suspected that there was a specific surface receptor on peritoneal macrophages responsible for the activation of macrophages by CnB and for the tumoricidal activity of CnB. It is noteworthy that there is a high concentration of calcineurin in blood and amniotic fluid as well as in the cytosol of cells (18) , which would permit CnB to interact with monocytemacrophages in vivo.
Integrin aM (CD11b/CD18, Mac-1) is a subunit of the heterodimeric integrin aMb 2 . This integrin, a member of the integrin superfamily, is expressed primarily on the surfaces of monocytes, macrophages, granulocytes, and NK cells, which perform some of the central functions of myeloid cells, including adhesion, migration, chemotaxis, phagocytosis, and respiratory burst activity (19) (20) (21) . Integrin aMb 2 is the most promiscuous member of the integrin family. More than 30 protein and nonprotein molecules have been reported to bind this receptor (22) . These ligands include ICAMs 1, 2, and 3 (23) , fibrinogen (24) , factor X (25), complement C3 fragment (26) , urokinase plasminogen activator receptor (27) , E-selectin (28) , catalase, transferrin (29) , and some nonprotein ligands such as LPS (30) and heparin (31) , etc.
TRAIL is a member of the TNF family of cytokines, which induces apoptosis of a variety of tumor cells by engaging the death receptors DR4 and DR5, despite displaying no cytotoxicity against most normal cells; this makes it a promising new agent for cancer therapy (32) (33) (34) . Although TRAIL is constitutively expressed in a wide variety of normal tissues, its main role appears to be in the immune system. It is expressed on activated T cells, NK cells, macrophages, monocytes, dendritic cells, and neutrophils and plays important roles in tumor surveillance and defense against viral infections and many other physiological and pathological processes (35, 36) . In immune cells, TRAIL is induced by several pathways including the type I or II IFN-mediated JAK/STAT (37) (38) (39) (40) and TLR agonist-mediated TLR pathways (41) (42) (43) . Histone deacetylase inhibitors induce TRAIL in human breast tumors via the transcription factor Sp1 (44) , and proline oxidase promotes TRAIL expression via NFAT (45) .
To examine whether there is a CnB receptor on peritoneal macrophages, we used a CnB affinity resin to trap potential receptors from highly purified peritoneal macrophage membranes. Mass spectrometry (MS) analysis showed that the binding protein was mouse integrin aM. Because CnB increased the expression of TRAIL, we tested whether this expression was mediated by integrin aM. To our knowledge, there is no report that TRAIL expression is correlated with integrin aM. If present, they would add new insights into the mechanisms regulating TRAIL expression and point to a strategy for drug screening based on the receptor.
Materials and Methods

Materials
Recombinant human CnB protein was prepared in our laboratory (the amino acid sequences of human, mouse, and rat CnB protein are identical). Endotoxin was removed with Cellufine ETclean S endotoxin-removing beads (Chisso). The purity of CnB was $98%, and LPS contamination was ,4 EU/mg. CnA was purified in our laboratory. Albumin egg (OVA), avidin, fibrinogen, LPS, unfractionated heparin, and polymyxin B sulfate were purchased from Sigma-Aldrich. Proteinase K (PK) was from Roche Diagnostics and IFN-g from Canspec Scientific Instruments (Shanghai, China). Anti-mouse integrin aM and the rat IgG2b k isotype control (functional grade purified) were purchased from eBioscience (San Diego, CA). TRAIL Ab for Western blotting was from Proteintech Group (Chicago, IL), and neutralizing TRAIL Ab was a gift from Dr. Dexian Zheng (Chinese Academy of Medical Sciences, Beijing, China). WGA-Sepharose and cyanogen bromide-activated Sepharose 4B were from Pharmacia. Small interfering RNA (siRNA) was purchased from Ribobio (Guangzhou, China), and the Annexin V/propidium iodide (PI) apoptosis detection kit was from Bender MedSystems.
Animals
Specific pathogen-free male Kunming mice and BALB/c mice, 6-8 wk of age, were purchased from the Department of Laboratory Animal Science of Peking University Health Science Center and Vital River Laboratories (Beijing, China), respectively. All animals were housed in microisolator cages with autoclaved food and bedding to minimize exposure to viral and microbial pathogens, and all procedures were approved by the Institutional Animal Care and Use Committee.
Cell isolation and culture
Resident peritoneal macrophages were harvested from the Kunming mice, washed, and resuspended in RPMI 1640 serum-free medium containing 50 U/ml penicillin and 50 mg/ml streptomycin. These cells were used for receptor purification and saturation binding assays or cultured on plates for TRAIL-related experiments. In most cases, they were plated in 12-well culture plates (2.5 3 10 6 cells/well) and incubated for 2 h at 37˚C in a 5% CO 2 atmosphere in a humidified incubator. Nonadherent cells were removed by washing three times with RPMI 1640 medium, and the adherent macrophages were cultured overnight in serum-free conditions before being exposed to drugs. RAW264.7 cells were cultured in DMEM supplemented with 10% heat-inactivated FBS. H22 hepatocarcinoma cells were obtained from H22 tumor-bearing Kunming mice and cultured in RPMI 1640 medium containing 10% heat-inactivated FBS. At the end of the period, the cell suspensions were filtered through Whatman GF/B glass fiber filters (Whatman) using a Brandel cell harvester (Brandel) and washed four times with cold PBS. The radioactivity retaining on the filters was measured using a Beckman 5500 g-counter (Beckman Coulter). To calculate specific binding, nonspecific binding (in the presence of an excess of unlabeled CnB) was subtracted from total binding (in the absence of unlabeled CnB). The maximum binding (Bmax) and K d were determined by Scatchard analysis.
Radiolabeling of CnB and receptor binding assays
Separation and purification of peritoneal macrophage membranes
Mouse peritoneal macrophages (5 g) were mixed with 5 volumes homogenate buffer (50 mmol/l HEPES [pH 7.4], 1 mmol/l CaCl 2 , 1 mmol/l PMSF, and 13protease inhibitor mixture), then homogenized with ∼30 strokes of a glass Dounce homogenizer on ice. The suspension was centrifuged at 4˚C and 600 3 g for 10 min to remove unbroken cells and nuclei. The pellet was discarded, and the supernatant was centrifuged at 8,000 3 g for another 10 min to remove mitochondria. The membranes were pelleted by ultracentrifugation (100,000 3 g, 20 min) and further purified by sucrose density gradient centrifugation. Thereafter, they were solubilized in 50 mmol/l HEPES (pH 7.4), 3% Triton X-100, 0.1 mmol/l PMSF, and 13 protease inhibitor mixture and incubated for 30 min at 4˚C with stirring. The suspension was clarified by centrifugation at 4˚C and 200,000 3 g for 30 min. The supernatant (7 ml) was mixed with 2 ml WGA-sepharose and incubated at 4˚C with stirring for 20 h. The sepharose was then transferred to a column and washed thoroughly with washing buffer (50 mmol/l HEPES [pH 7.4], 0.1% Triton X-100, 150 mmol/l NaCl, 10 mmol/l MgCl 2 , 0.1 mmol/l PMSF, and 13 protease inhibitor mixture), and the column was eluted with 15 ml elution buffer (50 mmol/l HEPES, 0.1% Triton X-100, 0.3 mol/l N-acetylglucosamine, 0.1 mmol/l PMSF, and 13 protease inhibitor mixture). One-milliliter fractions were collected, and protein concentrations were determined with a BCA Protein Assay Kit (Pierce).
Affinity purification of the CnB receptor and MS
CnB protein was coupled to cyanogen bromide-activated Sepharose 4B (Pharmacia). Fractions eluted from the WGA-sepharose column were incubated with CnB-sepharose for 20 h at 4˚C with stirring. Thereafter, the sepharose was transferred to a column and washed thoroughly with washing buffer (50 mmol/l HEPES [pH 7.4], 0.1% Triton X-100, 1 mol/l NaCl, 0.1 mmol/l PMSF, and 13 protease inhibitor mixture) and then eluted with 10 ml elution buffer (50 mmol/l HEPES, 0.1% Triton X-100, 0.6% octyl glucopyranoside, 1 mol/l NaCl, 0.1 mmol/l PMSF, and 13 protease inhibitor mixture). Specific binding of [ ]-CnB by adding bovine g-globulin and PEG 6000, followed by centrifugation. The supernatants were aspirated, and the radioactivity of the pellets was counted in a g counter. The ]-CnB binding activity was concentrated by centrifugal ultrafiltration and analyzed by SDS-PAGE (7.5% separating gel and 4% stacking gel). Protein bands were excised from the SDS-PAGE gels and transferred to a siliconized Eppendorf tube for trypsin digestion, and the resulting fragments were analyzed on a Qstar Pulsar I Quadrupole TOF-MS (Applied Biosystems/MDS Sciex, Toronto, ON, Canada). Proteins were identified either by peptide mass fingerprinting or tandem MS ion fragmentation using MASCOT software by searching the Swiss-Prot database.
RNA extraction and real-time PCR
Total RNA was extracted from peritoneal macrophages using an AxyPrep Multisource Total RNA Miniprep Kit (Axygen). Reverse transcription was performed with a PrimeScript 1st Strand cDNA Synthesis Kit (Takara Bio). Real-time PCR primers were designed with Primer 5.0 software, and the sequences were as follows: mouse TRAIL forward, 59-GCCACAGACAC-TTTCGGTGTT-39 and reverse, 59-TGATCTCATTTTGCGGAAAGAA-39; integrin aM forward, 59-AAACCACAGTCCCGCAGAGA-39 and reverse, 59-CGTGTTCACCAGCTGGCTTA-39; and b-actin forward, 59-AGAGGGAA-ATCGTGCGTGAC-39 and reverse, 59-CAATAGTGATGACCTGGCCGT-39. PCR was performed on an Applied Biosystems 7500 Real Time PCR system using SYBR Green Master Mix reagent (Applied Biosystems). Reactions were performed in triplicate.
Western blot analysis
Western blot analysis was performed on whole cell lysates of the peritoneal macrophages. Cell lysates were resolved by SDS-PAGE under reducing conditions and then electrotransferred to a nitrocellulose membrane (Millipore). The membrane was blocked with 5% nonfat milk and incubated with primary Ab for 2 h at room temperature, followed by biotin-conjugated species-specific secondary Ab for 1 h, then with avidin-HRP for 30 min. Protein bands were detected with SuperSignal ECL reagents (Pierce) and visualized by autoradiography.
RNA interference
RAW264.7 macrophages were transfected with siRNA targeting mouse integrin aM or negative control siRNA using HiPerFect Transfection Reagent (Qiagen) according to the manufacturer's instructions. In brief, cells were seeded at 3 3 10 5 cells/well in 12-well plates and incubated for 6 h in the presence of 750 ng siRNA complexed with 18 ml HiPerFect. Knockdown efficiency was assessed by quantitative PCR (qPCR) 48 h after transfection. The sequences of the siRNAs targeting integrin aM were as follows: siRNA1 sense, 59-GCACUGAGAUCCUGUUUAA dTdT-39 and antisense, 39-dTdT CGUGACUCUAGGACAAAUU-59; and siRNA2 sense, 59-GGAGAAUACUUAUGUGAAU dTdT-39 and antisense, 39-dTdT CCUCUU-AUGAAUACACUUA-59.
Flow cytometry
Competitive binding and apoptosis assays were performed by flow cytometry. In brief, peritoneal macrophages isolated as above were incubated with 10 mg/ml FITC-labeled avidin or 10 mg/ml FITC-labeled CnB for 1 h at 4˚C in the presence or absence of 10 mg/ml integrin aM mAb. The cells were washed twice and analyzed with an FACSVantage SE (BD Biosciences). H22 cells were cocultured with CnB-activated peritoneal FIGURE 2. Affinity purification of the CnB receptor from peritoneal macrophage membranes and SDS-PAGE analysis. A, CnA but not OVA binds to CnB affinity resin. CnA or OVA protein was incubated with CnB affinity resin or empty resin for 16 h at 4˚C. The fractions eluted from resins were concentrated and subjected to SDS-PAGE. Lanes 1 and 4, CnA and OVA protein input; lanes 2 and 5, fractions eluted from CnB affinity resin; and lanes 3 and 6, fractions eluted from empty resin. Proteins were stained with Coomassie brilliant blue. B, Binding activity profile of [ macrophages for 30 h, and then apoptosis of the H22 cells was examined by Annexin V-FITC/PI staining. The H22 cells were washed twice with ice-cold PBS and stained with 10 ml Annexin V and 5 ml PI in 200 ml binding buffer for 15 min at room temperature. After staining, 300 ml binding buffer was added to each tube, and samples were analyzed on the flow cytometer. Unstained cell sample and cells stained with Annexin V or PI only were prepared for fluorescence compensation.
In vivo tumor models
In the therapeutic model, BALB/c mice were i.p. inoculated with H22 hepatocarcinoma cells (1 3 10 6 ). Two days after injection of tumor cells, mice were treated with CnB, IFN-g, or normal saline for 10 d (i.p.). Survival following tumor challenge was recorded. In the prophylactic and therapeutic model, Kunming mice were treated with CnB, heat-inactivated CnB, or normal saline for 3 d (i.p.). Mice were then i.p. inoculated with H22 cells (1 3 10 6 ), followed by drug treatment for 7 d. All mice were sacrificed 60 d after tumor challenge.
Statistical analysis
Data are expressed as means and SEM. In vivo data were analyzed by twotailed t tests and the Gehan-Breslow-Wilcoxon test. A p value ,0.05 was considered statistically significant.
Results
CnB binds specifically to murine peritoneal macrophages
To determine if CnB binds specifically to murine peritoneal macrophages, we incubated the macrophages with different concentrations of [
125 I]-CnB on ice for 20 h, measured cell-bound radioactivity, and calculated the specific binding of [ 125 I]-CnB. The receptor saturation binding curve (Fig. 1 ) demonstrated specific binding; the Bmax was 1090 fmol/10 5 cells, and K d was 70.59 pM. These findings suggested that a high-affinity receptor for CnB was present on peritoneal macrophages.
Integrin aM is a receptor for CnB on murine peritoneal macrophages
We next investigated whether there was a receptor for CnB on the peritoneal macrophages. First, we assessed the availability and specificity of the CnB affinity resin. CnA was used as a positive control, and OVA was used as a negative control. It was shown that CnA but not OVA could specifically bind to CnB affinity resin ( Fig.  2A) , which is consistent with our knowledge of CnB. Next, highly purified peritoneal macrophage membranes prepared as described in Materials and Methods were incubated with CnB affinity resin for 16 h at 4˚C, and bound proteins were eluted with octyl glucopyranoside buffer. Fractions 7 and 8 showed specific binding of [ 125 I]-labeled CnB (Fig. 2B ). The fraction with maximum binding activity was concentrated and subjected to SDS-PAGE analysis. We observed three major bands at ∼160-170, 22-24, and 18 to 19 kDa, respectively (Fig. 2C) . MS analysis showed that the three bands were mouse integrin aM, Kunitz-type trypsin inhibitor, and CnB (Table I) . Integrin aM is a subunit of the integrin aM b2 (aMb 2 ) molecule, also known as Mac-1 or CR3. Kunitz-type trypsin inhibitor (24 kDa) is a known ligand of integrin aM (29). It is a widely used component of the protease inhibitor mixture and so present in the washing buffer and elution buffer. As for the CnB band, we suspect that it was the endogenous protein that had bound to integrin aM in the process of membrane 
FIGURE 3.
Integrin aM Ab blocks binding of FITC-CnB to peritoneal macrophages. A, Peritoneal macrophages (1 3 10 6 /ml) were incubated with 5 mg/ml integrin aM Ab (M1/70) or 5 mg/ml isotype Ab (rat IgG2b) for 30 min at room temperature, followed by staining with FITC-conjugated anti-rat IgG for 15 min at room temperature. Cells were washed three times before being analyzed by flow cytometry. The percentages of integrin aM-positive cells are indicated by the line M1. B, Integrin aM Ab blocks binding of FITC-CnB to peritoneal macrophages. Peritoneal macrophages (5 3 10 6 /ml) were incubated with 10 mg/ml FITC-CnB or FITCavidin for 1 h at 4˚C in the presence or absence of 10 mg/ml integrin aM Ab. Cells were washed twice and subjected to flow cytometry. The percentages of integrin aM-positive cells are indicated by the line M1. This figure is one representative result of three independent experiments. preparation and had then bound to the CnB affinity resin complexed with integrin aM.
Integrin aM Ab blocks binding of FITC-CnB to peritoneal macrophages
The above experiment showed that CnB could interact with integrin aM in the presence of detergent. We next asked whether it could bind under physiological conditions. First, we examined expression of integrin aM on the surface of peritoneal macrophages. As expected, .70% of the peritoneal macrophages were integrin aM positive (Fig. 3A) . Next, we performed a competition binding experiment to confirm the binding of CnB to integrin aM. This showed that FITC-CnB bound specifically to peritoneal macrophages and that binding was blocked by the addition of integrin aM Ab (Fig. 3B) .
CnB induces TRAIL gene expression in peritoneal macrophages in vitro and in vivo
Because CnB bound specifically to integrin aM on peritoneal macrophages, we tested whether it could activate the macrophages and induce the expression of important functional molecules. To address these questions, we measured the expression of several proinflammatory factors (TNF-a, IL-6, and IL-1b), chemokines (MIP-2, keratinocyte chemoattractant, and LPS-induced CXC FIGURE 4. CnB upregulates TRAIL expression in peritoneal macrophages in vitro and in vivo. A, CnB upregulates TRAIL expression at the mRNA level. Peritoneal macrophages were plated in 12-well culture plates (2.5 3 10 6 cells/well) and incubated with CnB or control proteins (avidin and fibrinogen) for 10 h. Total RNA was extracted, and TRAIL expression was analyzed by qPCR. Results were normalized to b-actin expression and are presented as fold increases over the medium-only control. B, CnB upregulates TRAIL expression at the protein level. Peritoneal macrophages were plated in six-well culture plates (6 3 10 6 cells/well) and incubated with different concentrations of CnB (5, 20, and 100 mg/ml) for 24 h. At the indicated time points, cells were lysed, and the lysates were immunoblotted with TRAIL Ab. C, Polymyxin B abrogates LPS-induced TRAIL expression but not CnBinduced TRAIL expression. Peritoneal macrophages were plated in 12-well culture plates (2.5 3 10 6 cells/well) and incubated with CnB (20 mg/ml) or LPS (30 ng/ml) for 10 h in the presence or absence of 10 mg/ml polymyxin B. TRAIL expression was analyzed by qPCR. D, PK digestion abolishes CnBinduced but not LPS-induced TRAIL expression. Peritoneal macrophages were incubated with CnB (20 mg/ml), PK-digested CnB (20 mg/ml), LPS (100 ng/ ml), or PK-digested LPS (100 ng/ml) for 10 h. TRAIL expression was analyzed by qPCR. E, CnB induces TRAIL expression in peritoneal macrophages in vivo. Kunming mice were divided into four groups (five mice/each group) and i.p. injected with different doses of CnB (20, 100, or 400 mg/mouse) or PBS. Mice were sacrificed at 12 h after injection, and peritoneal macrophages were harvested for RNA extraction. TRAIL expression was analyzed by qPCR. All experiments were performed more than three times, and the results are expressed as means 6 SE. *p , 0.05, **p , 0.01. chemokine) and some members of the TNF superfamily (Fas ligand, 4-1BBL, TRAIL, TNF-like weak inducer of apoptosis, LIGHT, and TL1). As expected, CnB upregulated expression of the proinflammatory factors chemokines and members of the TNF superfamily such as 4-1BBL, TRAIL, and TL1 (data not shown). However, CnB was no more effective than the control proteins used (fibrinogen and avidin) in inducing these genes (data not shown) except in the case of TRAIL. CnB markedly increased the expression of TRAIL in a dose-dependent manner at the mRNA and protein levels (Fig. 4A, 4B) . Fibrinogen is a known ligand of aMb 2 and was used as a receptor-related control, whereas avidin was used as a receptor-unrelated control. Because CnB was expressed and purified from bacterial cultures, and LPS can also induce TRAIL expression (30), we sought to distinguish the presumed CnB-induced TRAIL expression from LPS-induced TRAIL expression. We found that LPS-induced TRAIL expression was markedly inhibited by polymyxin B sulfate, whereas CnB-induced TRAIL expression was not (Fig. 4C) . Conversely, PK-digested LPS retained the ability to induce TRAIL expression, whereas PK-digested CnB did not (Fig.  4D ). These data demonstrate that the CnB-induced TRAIL expression was not due to contamination by LPS. Next, we further examined whether CnB could induce TRAIL expression in peritoneal macrophages in vivo. Kunming mice were divided into four groups and i.p. injected with different doses of CnB (20, 100, or 400 mg/ mouse) or PBS. We observed that CnB treatment groups showed more extensive production of TRAIL than the PBS treatment group, and the CnB 100 mg group showed the most extensive production of TRAIL comparing to the 20 and 400 mg groups (Fig. 4E) .
CnB-induced TRAIL expression is dependent on integrin aM
Because CnB increased the expression of TRAIL, we tested whether this expression was mediated by integrin aM. We found 6 cells/well) in serum-free conditions. They were pretreated with integrin aM Ab (final concentrations, 10, 20, and 30 mg/ml) or isotype Ab (final concentration, 20 mg/ml) for 30 min, followed by stimulation with 20 mg/ml CnB for 10 h. At the indicated time points, total RNA was extracted, and TRAIL expression was analyzed by qPCR. Results were normalized to b-actin expression and are presented as fold increases over the medium-only control. B, Unfractionated heparin inhibits CnB induced-TRAIL expression in peritoneal macrophages. Cells were pretreated with unfractionated heparin (final concentrations, 10, 30, and 300 U/ml) for 30 min, followed by stimulation with 20 mg/ml CnB for 10 h. TRAIL expression was analyzed by qPCR. C, Fibrinogen inhibits CnBinduced TRAIL expression in peritoneal macrophages. Cells were pretreated with fibrinogen (final concentrations, 100 and 300 mg/ml) for 30 min, followed by stimulation with 20 mg/ml CnB for 10 h. TRAIL expression was analyzed by qPCR. D, Efficiency of knockdown of integrin aM by siRNA in RAW 264.7 cells. RAW 264.7 cells were transfected with either negative control siRNA or integrin aM siRNA, and knockdown efficiency was assessed 48 h after transfection by qPCR. Integrin aM knockdown inhibits CnB induced-TRAIL expression (E) but not IFN-g induced-TRAIL expression (F) in RAW264.7 macrophages. Cells were transfected with either negative control siRNA or integrin aM siRNA. Thirty-six hours after transfection, cells were treated with 20 mg/ml CnB or 200 U IFN-g for 12 h, and TRAIL gene expression was analyzed by qPCR. All experiments were performed more than three times, and the results are expressed as means 6 SE.
that the induction of TRAIL was inhibited by pretreatment with integrin aM Ab (Fig. 5A) . The fact that the inhibition of TRAIL expression was incomplete may be due to partial activation of the macrophages by the binding of integrin aM Ab itself (48) (data not shown). We further examined whether known ligands of integrin aM could compete for binding of CnB to the receptor and reduce TRAIL expression. Unfractionated heparin is a strong ligand of integrin aMb 2 and can inhibit binding of fibrinogen, factor X, and iC3b to this receptor (31, 49) . CnB-induced TRAIL expression was 80% inhibited by preincubation with unfractionated heparin (Fig. 5B) as well as to some extent by fibrinogen (Fig. 5C) . Furthermore, CnB-induced TRAIL expression was 50-60% inhibited when we knocked down integrin aM in RAW 264.7 macrophages, whereas IFN-g-induced TRAIL expression was unaffected (Fig. 5E, 5F ). These results suggest that CnB-induced and IFN-g-induced TRAIL expression is mediated by different receptors and pathways.
The tumoricidal activity of CnB-activated peritoneal macrophage is partially dependent on TRAIL To determine if CnB-activated peritoneal macrophages play a key role in eradicating the H22 cells and to assess the role of TRAIL in this process, we established an in vitro model to mimic the killing process. In this model, H22 cells were cocultured with CnBstimulated peritoneal macrophages, and apoptosis was assayed.
LPS served as a positive control. We observed that CnB-activated peritoneal macrophages induced significant apoptosis in H22 cells from an E:T ratio of 5:1 to 20:1 (Fig. 6A) . Moreover, 5 mg/ml CnB was sufficient to activate the peritoneal macrophages and cause apoptosis of the H22 cells (Fig. 6B) . Next, we examined the role of TRAIL in tumor eradication by CnB-stimulated peritoneal macrophages. As expected, the early apoptosis of H22 cells was markedly inhibited by neutralizing TRAIL (Fig. 6C) . These data indicate that the tumoricidal activity of CnB-activated peritoneal macrophages is partially dependent on TRAIL.
CnB treatment significantly prolongs the survival of mice bearing H22 ascites tumors, which has a positive correlation with the induction level of TRAIL We had previously reported that i.p. injection of CnB prolonged the survival of mice bearing H22 ascites tumors. In this study, we repeated this experiment and further compared CnB with the classic immunotherapeutic drug IFN-g. We observed that CnB and IFN-g had equal effect on prolonging survival of mice bearing H22 ascites tumors (Fig. 7A) . It is known that induction of TRAIL expression in immune cells is an important antitumor mechanism of IFN-g. So we wondered whether CnB's antitumor effect was consistent with its TRAIL induction ability in peritoneal macrophages. We observed that CnB could not induce TRAIL expression in peritoneal macrophages if we boiled it for 20 min (inset of FIGURE 6 . Tumoricidal activity of CnB-stimulated peritoneal macrophages. A, Peritoneal macrophages were plated in 12-well culture plates (2.5 3 10 6 cells/well) and incubated with 20 mg/ml CnB for 10 h. They were then cocultured with H22 hepatocarcinoma cells at different E:T ratios for 30-36 h in serum-free conditions. H22 cells in the supernatants were harvested at the indicated time points and stained with FITC-Annexin V/PI, followed by flow cytometry analysis. B, Tumoricidal activity of CnB-stimulated macrophages at different drug concentrations. CnB-and LPS-stimulated macrophages were cocultured with H22 hepatocarcinoma cells for 30-36 h, and the H22 cells were harvested for apoptosis assay by Annexin V/PI staining. The lower right quadrant represents early apoptosis, and the upper right represents late apoptosis. C, The effect of neutralizing TRAIL in the coculture system. CnB-stimulated macrophages were cocultured with H22 cells for 30 h in the presence of 20 mg/ml of neutralizing TRAIL Ab or 20 mg/ml isotype Ab, and then the H22 cells were harvested, and apoptosis was assayed by Annexin V/PI staining. All experiments were performed more than three times, and the results are expressed as means 6 SE. Fig. 7B ). This heat-inactivated CnB failed in prolonging the survival of Kunming mice bearing H22 ascites tumors (Fig. 7B) , which was consistent with its weak ability to induce TRAIL expression in peritoneal macrophages. From these data, we speculate that TRAIL is the main candidate molecule responsible for the tumoricidal activity of CnB in vivo.
Discussion
We have shown above that CnB is a ligand of integrin aM, a subunit of the heterodimeric integrin aMb 2 . Integrin aMb 2 is expressed primarily on the surfaces of innate immune cells, which play important roles in cells adhesion, migration, chemotaxis, and phagocytosis. However, it remains unclear whether integrin aM promotes tumor progression or tumor regression. Several groups have reported that tumor-infiltrating integrin aM-positive cells support tumor growth by, for example, stimulating angiogenesis and neovascularization (50) (51) (52) . In contrast, integrin aMb 2 is crucial for effective FcR-mediated immunity to melanoma (53) and promotes the survival of mouse NK cells (54) . In addition, it inhibits TLR-triggered inflammatory responses and prevents excessive production of proinflammatory cytokines and type I IFN (55) . Recent research has highlighted a critical role for inflammation in the development of cancers, based on the observation that innate immune cells drive tumor progression by producing proinflammatory factors such as TNF-a and IL-6 (56-58). We have shown above that CnB binds and activates integrin aMb 2 on macrophages and induces high levels of the cytotoxic cytokine TRAIL but low levels of proinflammatory cytokines (data not shown) and so converts the inflammatory macrophages into cytotoxic macrophages. Therefore, integrin aMb 2 is a double-edged sword, and whether it promotes or inhibits tumor progression depends on its ligand. TRAIL induces apoptosis of a variety of tumor cells while displaying no cytotoxicity against most normal cells; this makes it a promising new agent for cancer therapy. It has been reported that in immune cells, TRAIL is induced mainly by the type I or II IFN-mediated JAK/STAT (37) (38) (39) (40) and TLR agonist-mediated TLR pathways (41) (42) (43) . To our knowledge, this is the first report that TRAIL expression is mediated by integrin aM, and our findings should add to understanding of the mechanisms regulating TRAIL expression. They also suggest a strategy for drug screening based on the integrin aM-TRAIL pathway; this might permit the identification of a peptide that induces high levels of TRAIL but low levels of proinflammatory cytokines among mutants of CnB or other ligands of integrin aM.
In vivo experiments above show that CnB as well as IFN-g can markedly prolong the survival of mice bearing H22 ascites tumors. However, IFN-induced immune toxicity has been a limiting factor that restricts the amount of IFN that can be used for effective cancer therapy (59) . In contrast with IFN-g, CnB has a lower toxicity in vitro and vivo. Acute toxicity experiment indicates that mice can endure at least a 50-fold normal dose of CnB (17). Besides, we observe that the antitumor effect of CnB is consistent with the TRAIL induction level by CnB. Heat-inactivated CnB fails in inducing TRAIL expression in peritoneal macrophages as well as in prolonging the survival of Kunming mice bearing H22 ascites tumors. This indicates that TRAIL is an important candidate molecule responsible for the tumoricidal activity of CnB in vivo. However, whether TRAIL is the only executing molecule in CnB-initiated tumoricidal action should be further examined in future studies.
Research on the functions of calcineurin in the immune system is mainly focused on aspects of adaptive immunity such as T cell activation. Our findings add new insights into the roles of CnB in the regulation of innate immunity. We suspect that the substantial levels of CnB in sera are important in sustaining innate immune responses and cancer immunosurveillance by activating monocytes/ macrophages. Our observations also suggest a possible application of CnB in cancer therapy because of its ability to induce high levels of TRAIL, low toxicity, and stability.
